Aegon Accelerates Execution of Strategy and Increases Expense Savings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Allergan (AGN) Receives Unfavorable PTAB Decision on RESTASIS-Related IPRs
December 8, 2016 3:41 PM ESTAllergan plc (NYSE: AGN) announced the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) granted Mylan Pharmaceutical Inc.'s Petitions to institute Inter Partes Reviews (IPRs) of U.S. Patent Nos. 8,629,111 (the "'111 patent"), 8,633,162 (the "'162 patent"), 8,642,556 (the "'556 patent"), 8,648,048 (the "'048 patent"),... More
